Skip to main content
Vita 34 AG logo

Vita 34 AG — Investor Relations & Filings

Ticker · V3V ISIN · DE000A0BL849 LEI · 529900OEWA4GSZEZ4P40 F Human health and social work activities
Open in API
Filings indexed 794 across all filing types
Latest filing 2017-08-10 Declaration of Voting R…
Country DE Germany
Listing F V3V

About Vita 34 AG

https://www.vita34.de/en/

Vita 34 AG is a biobank specializing in the cryopreservation of stem cells derived from umbilical cord blood and tissue. Established in 1997 as the first private cord blood bank in Europe, the company offers services for the long-term storage of perinatal stem cells for potential future medical applications. The service portfolio includes providing collection kits for childbirth, handling logistics, processing the biological material, and storing the stem cell deposits under cryogenic conditions. These services are offered to expectant parents as a form of private medical provision for their child and family. As part of the Famicord Group, Vita 34 is also involved in research and development related to cell-based therapies.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains sections like 'Notification of Major Holdings', detailing changes in voting rights percentages (crossing thresholds from 9.39% to 11.64%) as per Article 26, Section 1 of the WpHG (German Securities Trading Act). This directly corresponds to the definition of a major shareholding notification, which is classified under the code MRQ (Major Shareholding Notification). Although the header mentions 'Voting Rights Announcements', the content is a formal notification of a change in ownership stake crossing a reporting threshold, which MRQ covers better than DVA (Declaration of Voting Results).
2017-08-10 English
Vita 34 adjusts targets for 2017 and increases capital market communication
Regulatory Filings Classification · 95% confidence The document is a news release dated August 8, 2017, announcing an adjustment to the 2017 revenue and earnings targets following an acquisition (Seracell). It also explicitly mentions an 'intensification of investor relations activities planned' and the hiring of a manager for the 'relaunch of the investor relations activities'. This content—a corporate update regarding financial forecasts and investor communication strategy—does not fit the specific definitions for 10-K, AR, ER, IR, or CT. Since it is a general corporate announcement disseminated via DGAP (a service often used for regulatory news), and it deals with forward-looking statements and strategic changes rather than a specific mandatory filing like a dividend notice or director dealing, it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous corporate news item, or potentially a very broad interpretation of an Earnings Release (ER) if it were more focused on results, but here the focus is on *target adjustment* and *IR intensification*. Given the options, RNS serves as the best general regulatory announcement fallback for significant, non-standard corporate news that isn't a full report or a specific event announcement like a merger or dividend.
2017-08-08 English
Vita 34 adjusts revenues and earnings targets for 2017
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc' announcement dated August 8, 2017, disclosing an 'inside information acc. to Article 17 MAR' (Market Abuse Regulation). The core content involves the company, Vita 34 AG, adjusting its revenue and earnings targets for the 2017 financial year. This type of announcement, which provides key financial updates outside of a full periodic report (like 10-K or IR), fits best under the 'Earnings Release' (ER) category, as it is an immediate release of updated financial performance expectations. Although it's a forecast adjustment rather than a final result, it serves the function of an earnings-related communication. It is too specific for the general 'RNS' fallback, and it is not a full report, transcript, or management discussion. FY 2017
2017-08-08 English
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Vita 34 AG: Release according to Article 26a of the WpHG' and specifically announces the 'Publication of total number of voting rights' as of 31.07.2017. It details a 'Type of capital measure' which is a 'Conditional capital increase' and states the 'New total number of voting rights'. This content directly relates to changes in the company's capital structure and the resulting voting rights, which aligns best with the 'Capital/Financing Update' (CAP) category, as it is a formal announcement regarding capital structure changes (conditional capital increase). While it involves voting rights, it is not the *result* of a shareholder vote (DVA), but rather an update on the total number of shares/rights due to a capital measure. Given the focus on capital structure change, CAP is the most precise fit.
2017-07-31 English
Vita 34 completes rights issue - multiple times oversubscribed
Capital/Financing Update Classification · 99% confidence The document is a news release dated July 28, 2017, announcing that Vita 34 AG has completed a rights issue (capital increase) which was oversubscribed. Key phrases include 'completes rights issue', 'Key word(s): Capital Increase', and details about the issuance of new shares and the intended use of proceeds (acquisition of Seracell Pharma AG). This content directly relates to fundraising, financing activities, and changes in capital structure. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV).
2017-07-28 English
DGAP-DD: Vita 34 AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding a transaction by a 'person discharging managerial responsibilities' (Steffen Richtscheid, Member of the administrative or supervisory body). It follows the structure typical of insider transaction disclosures, detailing the person, the issuer (Vita 34 AG), the financial instrument, the nature of the transaction ('Buy of new shares via exercise of subscription rights'), price, volume, and date. This directly corresponds to the definition for Director's Dealing (DIRS). The document length is short (2162 chars), but the content is the primary disclosure itself, not an announcement of a report, thus DIRS is the correct classification over RPA or RNS.
2017-07-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.